Zheng Suxin, Chen Yu, Donahue Christine P, Wolfe Michael S, Varani Gabriele
Department of Chemistry, University of Washington, Seattle, 98195, USA.
Chem Biol. 2009 May 29;16(5):557-66. doi: 10.1016/j.chembiol.2009.03.009.
Some familial neurodegenerative diseases are associated with mutations that destabilize a putative stem-loop structure within an intronic region of the tau pre-messenger RNA (mRNA) and alter the production of tau protein isoforms by alternative splicing. Because stabilization of the stem loop reverses the splicing pattern associated with neurodegeneration, small molecules that stabilize this stem loop would provide new ways to dissect the mechanism of neurodegeneration and treat tauopathies. The anticancer drug mitoxantrone was recently identified in a high throughput screen to stabilize the tau pre-mRNA stem loop. Here we report the solution structure of the tau mRNA-mitoxantrone complex, validated by the structure-activity relationship of existing mitoxantrone analogs. The structure describes the molecular basis for their interaction with RNA and provides a rational basis to optimize the activity of this new class of RNA-binding molecules.
一些家族性神经退行性疾病与突变相关,这些突变会破坏tau前体信使核糖核酸(mRNA)内含子区域内一个假定的茎环结构,并通过可变剪接改变tau蛋白异构体的产生。由于茎环的稳定会逆转与神经退行性变相关的剪接模式,稳定该茎环的小分子将为剖析神经退行性变机制和治疗tau蛋白病提供新方法。抗癌药物米托蒽醌最近在高通量筛选中被鉴定出可稳定tau前体mRNA茎环。在此,我们报道了tau mRNA-米托蒽醌复合物的溶液结构,并通过现有米托蒽醌类似物的构效关系进行了验证。该结构描述了它们与RNA相互作用的分子基础,并为优化这类新型RNA结合分子的活性提供了合理依据。